Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Current Prescription Status of Contraindicated Drug Combinations Causing Serotonin Syndrome: Analysis of HIRA-NPS Data

  • Jae Gon, Ryu (Department of Pharmacy, Sungkyunkwan University Samsung Changwon Hospital) ;
  • So Young, Kim (Department of Pharmacy, Kosin University Gospel Hospital) ;
  • Susin, Park (College of Pharmacy, Woosuk University) ;
  • Nam Kyung, Je (College of Pharmacy, Pusan National University)
  • Received : 2022.07.05
  • Accepted : 2022.10.31
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Serotonin syndrome is a life-threatening disease if not appropriately treated. This study aimed to investigate the prescription status of contraindicated drug combinations that cause serotonin syndrome and identify the related factors. Methods: A cross-sectional study was conducted using nationwide claims data. Adult patients taking serotonergic drugs with Parkinson's disease or mental disorders were selected. Based on international medical databases (MDBs) and the Korean Drug Utilization Review (DUR), the status of prescribing contraindicated drug combinations that induce serotonin syndrome, the related factors, and the difference between international MDBs and the Korean DUR were analyzed. Results: Of the 49,773 study subjects, 163 (0.3%) were prescribed contraindicated serotonergic drug combinations based on international MDBs, and among them, only 105 (64.4%) were contraindicated by the Korean DUR. Positive influencing factors for prescribing contraindicated drug combinations include patient age between 65 and 74 and physician's specialties (neurologists, and orthopedists). Negative influencing factors were physician's specialty (internists) and medical institution (primary institutions). Conclusion: Despite the implementation of DUR, 3 out of 1,000 study subjects received contraindicated drug combinations that caused serotonin syndrome. Hence, it is necessary to comply with the DUR and improve it in accordance with international MDBs.

Keywords

Acknowledgement

This study is based on data from the Korea Health Insurance Review and Assessment Service (HIRA-NPS-2020); however, the results are not related to the HIRA or Ministry of Health and Welfare.

References

  1. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.  https://doi.org/10.1176/ajp.148.6.705
  2. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.  https://doi.org/10.1056/NEJMra041867
  3. Asch DA, Parker RM. The Libby Zion Case. N Engl J Med 1988;318:771-5.  https://doi.org/10.1056/NEJM198803243181209
  4. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999;33:457-9.  https://doi.org/10.1016/S0196-0644(99)70313-6
  5. Parrott A. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837-44.  https://doi.org/10.1016/S0091-3057(01)00711-0
  6. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999;19:894-6.   https://doi.org/10.1592/phco.19.10.894.31561
  7. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998;32:33-8.  https://doi.org/10.1345/aph.17204
  8. Giese SY, Neborsky R. Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl. Plast Reconstr Surg 2001;107:293-4  https://doi.org/10.1097/00006534-200101000-00069
  9. DeSilva KE, Le Flore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-5.  https://doi.org/10.1097/00002030-200107060-00010
  10. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs 1998;30:367-9.  https://doi.org/10.1080/02791072.1998.10399712
  11. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 2001;61:2163-75.  https://doi.org/10.2165/00003495-200161150-00002
  12. Lange-Asschenfeldt C, Weigmann H, Hiemke C, et al. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J Clin Psychopharmacol 2002;22:440-1.  https://doi.org/10.1097/00004714-200208000-00022
  13. Turkel SB, Nadala JGB, Wincor MZ. Possible serotonin syndrome in association with 5-HT3 antagonist agents. Psychosomatics 2001;42:258-60.  https://doi.org/10.1176/appi.psy.42.3.258
  14. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000;79:201-9.  https://doi.org/10.1097/00005792-200007000-00001
  15. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4. 
  16. Werneke U, Truedson-Martiniussen P, Wikstrom H, et al. Serotonin syndrome: A clinical review of current controversies. J Integr Neurosci 2020;19:719-27.  https://doi.org/10.31083/j.jin.2020.04.314
  17. Nguyen CT, Xie L, Alley S, et al. Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: A Retrospective Study Utilizing Two Large US Claims Databases. Prim Care Companion CNS Disord 2017;19. 
  18. Choi NK, Park BJ. Strategy for establishing an effective Korean drug utilization review system. J Korean Med Assoc 2010;53:1130-8.  https://doi.org/10.5124/jkma.2010.53.12.1130
  19. Jang C, Yoo KB, Kim W, et al. New Alert Override Codes for the Drug Utilization Review System Derived from Outpatient Prescription Data from a Tertiary Teaching Hospital in Korea. Healthc Inform Res 2016;22:39-45.  https://doi.org/10.4258/hir.2016.22.1.39
  20. Kim DS, Je NK, Park J, et al. Effect of nationwide concurrent drug utilization review program on drug-drug interactions and related health outcome. Int J Qual Health Care 2021;33. 
  21. Cho YH, Kim KJ. The Evaluation of Drug Utilization Review on Potentially Inappropriate Medications for Elderly Patients in a Tertiary Hospital. Korean J Clin Pharm 2019;29:25-32.  https://doi.org/10.24304/kjcp.2019.29.1.25
  22. Park H-Y, Sohn HS, Kwon J-W. Reviews on the Current Status and Appropriate Management of Polypharmacy in South Korea. Korean J Clin Pharm 2018;28:1-9.  https://doi.org/10.24304/kjcp.2018.28.1.1
  23. Choi JS, Lee JH, Park SK, et al. Serotonin syndrome following duloxetine administration in a fibromyalgia patient: case report and literature review. J Rheum Dis 2016;23:332-5.  https://doi.org/10.4078/jrd.2016.23.5.332
  24. Yildirim V, Serkan G. Serotonin syndrome after clomipramine overdose in a child. Clin Psychopharmacol Neurosci 2016;14:388-90.  https://doi.org/10.9758/cpn.2016.14.4.388
  25. Joe S, Kim E, Park J, et al. Famotidine-induced reversal of meperidine-related serotonin syndrome: a case report. Korean J Anesthesiol 2017;70:221-3.  https://doi.org/10.4097/kjae.2017.70.2.221
  26. Kim L, Sakong J, Kim Y, et al. Developing the inpatient sample for the National Health Insurance claims data. Health Policy and Management 2013;23:152-61.  https://doi.org/10.4332/KJHPA.2013.23.2.152
  27. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.  https://doi.org/10.4178/epih/e2014008
  28. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010;74:1143-8.  https://doi.org/10.1212/WNL.0b013e3181d7d8e2
  29. McCormack PL. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. CNS drugs 2014;28:1083-97.  https://doi.org/10.1007/s40263-014-0206-y
  30. Kakkar AK, Dahiya N. Management of Parkinson's disease: Current and future pharmacotherapy. Eur J Pharmacol 2015;750:74-81.  https://doi.org/10.1016/j.ejphar.2015.01.030
  31. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007;27:161S-73S.  https://doi.org/10.1592/phco.27.12part2.161s
  32. Wong SL, Gilmour HL, Ramage-Morin PL. Parkinson's disease: Prevalence, diagnosis and impact. Statistics Canada Ottawa; 2014. 
  33. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.  https://doi.org/10.1001/jama.281.4.341
  34. Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80:851-7.  https://doi.org/10.1136/jnnp.2008.168211
  35. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.  https://doi.org/10.2165/00003088-200443130-00004
  36. Kim K, Lee H, Shin JY. Explosive Increase in Tramadol Use in Korea 2003-2013: Analysis of Patient Trends Based on the Korea National Health Insurance Database. J Psychoactive Drugs 2020;52:153-61.  https://doi.org/10.1080/02791072.2019.1612125
  37. Frank C. Recognition and treatment of serotonin syndrome. Can Fam Physician 2008;54:988-92. 
  38. Schmidt AW, Lebel LA, Howard HR, Jr., et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.  https://doi.org/10.1016/S0014-2999(01)01188-8
  39. Lin PY, Hong CJ, Tsai SJ. Serotonin syndrome caused by ziprasidone alone. Psychiatry Clin Neurosci 2010;64:338-9. 
  40. Racz R, Soldatos TG, Jackson D, et al. Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis. Clin Transl Sci 2018;11:322-9. https://doi.org/10.1111/cts.12543